Fibreoptic bronchoscopy with bronchoalveolar lavage (BAL) is used for clinical investigation and research into pulmonary complications of stem cell transplantation. Adverse effects of BAL are common in neutropenic patients with lung disease; there are few data on its safety when used routinely in transplant recipients without lung impairment. We describe the complications and usefulness for infection surveillance of routine BAL pre-transplantation and during neutropenia. Thirtythree patients before autologous or allogeneic BMT or PBSCT (B1) and 24 during post-transplant neutropenia (B2) underwent BAL; patients with pulmonary disease were excluded. Subjects were monitored for adverse effects, and BAL fluid was examined for pathogens.
Fibreoptic bronchoscopy with bronchoalveolar lavage (BAL) is widely used to investigate pulmonary abnormalities following stem cell transplantation, [1] [2] [3] [4] and is reported to be valuable in routine surveillance for infection at the onset of neutropenia. 5 It is a useful research method in the study of lung defence mechanisms, which are poorly understood in this patient group. 6, 7 There are, however, no adequate reports of the safety of BAL in transplant patients without respiratory disease, particularly those who are neutropenic and thrombocytopenic.
Reported BAL complication rates between 1.7% and 27% in transplant recipients with respiratory impairment [2] [3] [4] 8 have led to suggestions that the place of bronchoscopy in the bone marrow transplant unit should be reassessed, as its longerterm benefits are difficult to demonstrate. 3, 4 Its use as a research or surveillance tool must therefore be based on clear evidence of its safety. Most reports of BAL in transplant recipients without respiratory impairment imply acceptable safety without detailing complications, 5, 7, [9] [10] [11] [12] [13] and where rates are quoted they are low (eg 2% 14 ). The subjects of these reports were not neutropenic. One report of routine bronchoscopy 'at the onset of granulocytopenia' denies significant complications, but does not specify the subjects' ANC. 5 The clinical significance of potential pathogens identified in BAL fluid (BALF) from transplant recipients without respiratory impairment is unclear. 12, 14 Pathogens isolated pre-transplant have not been shown to relate to later complications, but pathogens detected at the onset of neutropenia in asymptomatic subjects have been reported to be clinically relevant. 5 We have performed fibreoptic bronchoscopy with BAL before transplantation and during post-transplant neutropenia in stem cell transplant recipients without apparent respiratory disease. These procedures were performed as part of a study into the mechanisms of post-transplantation lung disease. We report the complications of bronchoscopy and BAL, and its clinical usefulness for infection surveillance. Neutropenic and thrombocytopenic patients show high rates of fever and bleeding whether or not they undergo invasive procedures, so the frequency of adverse events observed following bronchoscopy is compared with that seen in a control group of post-transplant neutropenic subjects.
Materials and methods

Subjects
Consecutive patients attending the Western General Hospital haematology and oncology units for autologous or sibling-donor allogeneic BMT or PBSCT were invited to take part in the study. All subjects gave informed consent to an ethically approved study of lung injury in stem cell transplant recipients, involving fibreoptic bronchoscopy with BAL before transplantation and during neutropenia. Subjects were excluded if they withheld consent or if the responsible clinicians advised against bronchoscopy for medical or psychological reasons. Bronchoscopy during neutropenia required reconfirmation of consent and medical fitness. As the topic of this report is bronchoscopy in the absence of clinical indications, subjects have been excluded if they showed evidence at the time of bronchoscopy of respiratory impairment, defined as new chest radiographic abnormalities or fever (Ͼ38°C) plus hypoxia (sustained fall of Ͼ5% from baseline S a O 2 ).
Events in the bronchoscopy group were compared with a neutropenic group (group C) who did not undergo bronchoscopy. These were stem cell transplant recipients treated in the Western General Hospital during the period of the study under the same protocols as the bronchoscopy subjects, who gave consent to the research study but declined bronchoscopy during neutropenia. Subjects who at the relevant time (day 6 post transplant, see below) showed signs of respiratory impairment were excluded.
Bronchoscopy
Pre-transplant bronchoscopy and BAL (B1) took place before any conditioning chemotherapy or radiotherapy, but after the maximum possible recovery time following any previous cytotoxic therapy. Post-transplant bronchoscopy and BAL (B2) was performed as soon as feasible after the ANC fell below 0.5 × 10 9 /l. Subjects were instructed not to eat or drink for 4 h before bronchoscopy. Those with a platelet count below 40 × 10 9 /l were given a platelet infusion (200-250 ml containing at least 220 × 10 9 platelets) starting not more than 1 h before bronchoscopy. Thrombocytopenic subjects known to be refractory to platelet transfusion were not studied.
All bronchoscopic procedures were performed by one physician (ATW). Most B1 procedures took place in a dedicated endoscopy suite, using an Olympus BF P200 videoscope, tip diameter 5.3 mm (Olympus, Southend-on-Sea, UK). All B2 and the remaining B1 procedures were performed in single-patient rooms with an Olympus BF P20 D fibreoptic scope, tip diameter 4.9 mm. Subjects were sedated with i.v. midazolam (3-20 mg Hypnovel; Roche, Welwyn Garden City, UK) and either phenoperidine (0.5-1.0 mg Operidine; Janssen, High Wycombe, UK) or fentanyl (50-100 g Sublimaze; Janssen-Cilag, High Wycombe, UK) unless they were receiving other regular opiates. Up to 15 ml 4% lignocaine spray was applied to the nose and mouth and inhaled into the lower respiratory tract, followed if necessary during bronchoscopy by 4-12 ml 2% lignocaine to the larynx and 4-16 ml 1% lignocaine to the lower respiratory tract. Supplementary oxygen was given by nasal cannulae at 2-4 l/min.
The bronchoscope was passed nasally when possible without trauma to the mucosa. If resistance was felt in both nostrils then it was passed orally using a flanged mouthpiece held between the subject's teeth. The bronchi were inspected to segmental level: to minimise mucosal damage, subsegmental inspection was not attempted. All secretions were aspirated and collected. For BAL, the bronchoscope tip was wedged in a subsegmental bronchus of the middle lobe or lingula. Up to 240 ml of normal saline at 37°C was instilled in 30 ml aliquots, with gentle aspiration after each aliquot. The aspirate from the first aliquot was used for microbiological analysis, and subsequent aspirates were retained for further research analysis. Lavage was stopped if the subject began coughing excessively, to avoid mucosal trauma. Following lavage the scope was withdrawn slowly, with continuous gentle suction up to mid-trachea. The aspirates were pooled for microbiological analysis.
Pulse rate and arterial oxygen saturation were monitored by pulse oximetry from the time of administration of sedation until full recovery. Temperature and blood pressure were recorded before and at 15 min intervals for 2 h after the procedure, and then every 4 h for 24 h for inpatients. Adverse events were sought by asking the subjects on the day after bronchoscopy, and by examination of the nursing observation charts and medical records. The following were regarded as complications of bronchoscopy if they occurred within 24 h of the procedure:
(1) reported or witnessed bleeding from the mouth, nose or respiratory tract; (2) new fever greater than 38°C on any single reading; (3) arterial oxygen desaturation to below 90% while breathing air after the completion of the lavage procedure; (4) hypotension below a systolic pressure of 80 mmHg; (5) subject complaints of cough or other respiratory symptoms.
Isolation of pathogens
All BALF specimens were cultured for pathogenic bacteria including legionella, and examined for mycobacteria by auramine staining and 8 week culture. Filamentous fungi were sought by microscopy with fluorescent stains and by culture. Virological examination consisted of fluorescent antibody testing (FAT) and culture. For FAT a 'respiratory pool' of antibodies was used, covering influenza A and B, parainfluenza 1-3, respiratory syncytial virus and adenovirus. CMV was sought by FAT for early viral gene products in shell vial fibroblast culture, and by routine culture. FAT was also used to test for Pneumocystis carinii. Venous blood for aerobic and anaerobic culture was taken during any episode of fever Ͼ38°C.
Statistical analysis
Parametric variables were compared with Student's t-test, non-parametric with the Mann-Whitney rank sum test.
Comparisons of categories and proportions were by Fisher exact test where numbers were small or by 2 test. Calculations were performed with Sigma-Stat for Windows 1.0, Jandel Corporation (Erkrath, Germany).
Results
Subject characteristics
Thirty-three subjects (18 female, median age 41 (range 18-60) years) underwent B1. During post-transplant neutropenia, 29 bronchoscopies were performed in 27 subjects. Five of these procedures have been excluded from this report as the subjects showed signs of respiratory impairment, leaving 24 B2 procedures in 24 subjects (13 female, age 45 (18-60) years), of whom 23 had also undergone B1. Table 1 Diagnosis and transplant type of subjects undergoing pretransplant bronchoscopy (B1, n = 33), bronchoscopy during neutropenia (B2, n = 24), and of neutropenic comparison group (C, n = 35)
B1
B2 C
Diagnosis
Of 38 subjects initially recruited for group C, three were excluded because of respiratory impairment, leaving 35 (19 female, age 44 (18-63) years). Six group C subjects had undergone B1. Subjects' diagnoses, transplant type and conditioning are detailed in Table 1 . The differences between groups B2 and C in age, sex, transplant type, diagnosis and conditioning regimen were not significant (all P Ͼ 0.1).
Timing and route of bronchoscopy
B1 was performed a median of 9 (range 1-38) days before the return of stem cells. Nineteen subjects remained as inpatients after the procedure and were under observation for at least 24 h. Fourteen subjects underwent B1 as outpatients and were discharged after 3-6 h observation. B2 took place 6 (3-11) days after stem cell return; all subjects were inpatients. The reference time for events occurring in group C was therefore 6 days post transplant. The condition of B1, B2 and C subjects at the time of bronchoscopy is described in Table 2 . There was no significant difference Table 2 Condition of subjects at time of bronchoscopy (B1 or B2), or on day 6 post transplant for neutropenic comparison group (C) between group B2 at the time of bronchoscopy and group C on day 6 in any blood count parameter (all P Ͼ 0.05) or in current therapy (all P Ͼ 0.1). Although a larger number in group C than B2 had pre-existing fever, this was not significant (P ϭ 0.07). In six B1 and two B2 procedures, the bronchoscope was passed orally; all other procedures were transnasal.
Complications of pre-transplant bronchoscopy and BAL
Of 33 subjects undergoing B1, adverse events were detected in six (18%).
(1) Two outpatient subjects (one with non-Hodgkin's lymphoma and ANC 1. Blood cultures showed no growth in any of the B1 subjects who developed post-bronchoscopy fever. BALF from one subject with transient fever was later reported to show a rhinovirus on culture.
Complications of bronchoscopy and BAL during neutropenia
Adverse events were detected in eight (33%) of 24 subjects undergoing B2.
(1) Six (26%) of 23 previously apyrexial B2 subjects showed fever Ͼ38°C in the 24 h after bronchoscopy (range 6-16 h). All received i.v. antibiotics according to unit policy. In group C, three (11%) of 27 previously apyrexial subjects developed fever Ͼ38°C during day 6. The difference between B2 and C in rates of new fever was not significant (P = 0.3), and nor was the difference between B2 and B1 (P = 0.3). Two of six BALF specimens from B2 subjects who developed fever grew potentially pathogenic bacteria (one Escherichia coli, one ␣-haemolytic streptococcus). Blood cultures taken during fever from the latter subject grew a different organism (micrococci). One subject with a post-bronchoscopy fever had a positive blood culture (Streptococcus mitis) but no growth from BALF. (2) One subject with a post-transfusion platelet count of 46 × 10 9 /l suffered a nosebleed from the relevant nostril 4 h after withdrawal of the bronchoscope. This resolved without haemodynamic compromise or further intervention. Two of 35 group C subjects had nosebleeds during day 6. (3) One subject showed a single pulse oximetry reading of 87% while breathing air 2 h post-bronchoscopy, but was normal at 4 h.
Isolation of pathogens
Seven potentially pathogenic organisms were identified in six (18%) of 33 B1 BALF specimens. One specimen grew Escherichia coli and showed CMV on shell vial culture FAT. Single isolates were Staphylococcus aureus, Aspergillus fumigatus (small numbers on culture, no hyphae on microscopy), Rhodotorula rubra (yeast), rhinovirus, and an equivocal identification of a single Pneumocystis carinii organism. No additional therapy was required in any of these cases, as either the subjects were already receiving appropriate prophylactic therapy or the responsible physicians judged it unlikely that the isolate was of clinical significance. No subjects subsequently developed infective complications that could be ascribed to the organisms isolated. Four potentially pathogenic organisms were identified in three (13%) of 24 B2 BALF specimens. One specimen grew ␣-haemolytic streptococci and a yeast, Torulopsis glabrata. This subject showed no clinical signs of infection until he developed a fever 6 days after bronchoscopy while still neutropenic, with no apparent respiratory disease. Single isolates were of ␣-haemolytic streptococci and Escherichia coli. As noted above, both these subjects developed fever within 24 h of bronchoscopy; these organisms were not isolated on blood culture and the subjects did not subsequently develop symptoms or signs of respiratory infection.
Discussion
This is the first account of the safety of routine bronchoscopy in neutropenic and thrombocytopenic stem cell transplant recipients without respiratory disease. There were no major complications and no excess bleeding compared to the comparison group who did not undergo bronchoscopy. There was a trend to a higher incidence of fever in the 24 h after bronchoscopy: this did not reach statistical significance in comparison with the neutropenic control group, and would need to be confirmed in larger studies. None of our subjects suffered long-term ill effects from these episodes of fever. However, the requirement for broad-spectrum antibiotics following bronchoscopy is not a trivial consequence, as it reduces the treatment options available for subsequent episodes of sepsis occurring while the subjects remain neutropenic.
Fever was also the most frequent complication of pretransplant bronchoscopy. Two of the four episodes observed had significant consequences, in that the subjects required hospital admission and i.v. antibiotics. It should be noted that one of these subjects was already neutropenic due to his underlying disease, and the other had an alternative explanation for bacteraemia with the unblocking of a previously obstructed central venous catheter. Although the frequency of fever after BAL in our non-neutropenic subjects was less than half that in the neutropenic BAL subjects, this again did not reach statistical significance because of the sample size. It is possible that fever in the B1 subjects who were outpatients was under-reported, which would further reduce the significance of this observation. One additional potentially serious complication was an episode of vomiting during BAL. This is a recognised complication of any bronchoscopic procedure; the risk is minimised by effective topical anaesthesia. We believe that this subject had drunk alcohol heavily the night before the procedure. There were no long-term ill-effects from any pre-transplant bronchoscopy.
Fever complicating BAL is well recognised, with a reported incidence between 10 and 73% in different subject groups. 15, 16 Its incidence in previously apyrexial neutropenic patients without pulmonary infection has not been described before. It appears to be associated with BAL rather than simply bronchoscopy, 17 and occurs more frequently with larger volume lavage and coexistent pulmonary infection, 16, 18 but a rate of 50% has been reported with 200 ml lavage in normal volunteers. 19 We used a relatively large volume lavage (up to 240 ml), as one purpose of our study was to obtain alveolar macrophages for further research. Infection surveillance alone could be performed with a smaller volume (eg 120 ml 5 ) and a lower fever rate would then be expected. The fever is associated with pyrogenic cytokine release rather than bacteraemia in most cases, 15, 20, 21 although bacteraemia has been demonstrated after rigid bronchoscopy. 22 Our study has not demonstrated any clear-cut cases of BAL during neutropenia causing bacteraemia: two of the three neutropenic subjects who were found to have pathogenic bacteria in BALF subsequently developed fever, but so did four others, and none of the BALF organisms were found on blood culture.
We have found no evidence that bronchoscopy with BAL should have a place as part of routine infection surveillance before stem cell transplantation or during neutropenia. The yield of pathogenic organisms was low and none of the isolates proved to be of clinical significance. They are likely to have represented transient colonisation of the respiratory tract without established infection, or contamination from the nasopharynx. In contrast, Vaughan et al 5 found that five of eight isolates from 47 subjects at 'preaplasia' BAL were implicated in later fatal respiratory complications. The difference between these findings and our own may reflect changing antibiotic regimens or different patient populations, but the different timing of the procedures is notable. Our subjects were at the nadir of neutropenia rather than pre-aplasia when studied, and we excluded those who had already developed respiratory disease. It is possible that surveillance would be more productive if performed before the onset of neutropenia. The conclusions drawn from this study are limited by the relatively small number of subjects, particularly in the neutropenic BAL group. Larger numbers will be required before a definite conclusion as to the safety of BAL as a research or surveillance procedure in neutropenic posttransplant patients can be reached, and we believe that any group performing such procedures should report their safety record in order to build up a body of evidence. The pulmonary complications of stem cell transplantation will continue to be a major clinical problem as the indications for transplantation expand, and BAL remains a useful technique in understanding the underlying mechanisms. We have shown that BAL can be performed without major complications both before transplantation and more particularly during neutropenia. It does, however, require additional blood product therapy and is likely to increase the incidence of fever during neutropenia, hence increasing antibiotic use. This should be taken into account in the justification of future studies.
